FOR IMMEDIATE RELEASE

Company Name	Kyowa Kirin Co., Ltd.
Representative	Abdul Mullick, President and COO (Code No. 4151, Prime Market of TSE)
Inquiries	Hiroki Nakamura, Executive Vice President, Corporate Communications Department Media Contact: +81-3-5205-7205 Investor Contact: +81-3-5205-7206

Notice Regarding the Discontinuation of Rocatinlimab Clinical Trials

TOKYO, Japan, March 3, 2026 - Kyowa Kirin Co., Ltd. (the "Company") today announced that, based on the latest safety information and a comprehensive risk–benefit assessment, it has decided to discontinue all ongoing clinical trials for rocatinlimab, which has been evaluated for potential indications including moderate-to-severe atopic dermatitis.

1. Outline and background of this matter

As announced in the "Notice Regarding Kyowa Kirin Regaining Control of Rocatinlimab Development and Commercialization Program" dated January 30, 2026, the Company had regained control of the global rocatinlimab program and had been preparing for regulatory submission planned for the first half of 2026.

In late February 2026, safety update from the global rocatinlimab clinical program, including the Phase 3 "ROCKET" program for patients with moderate-to-severe atopic dermatitis was provided to the Company. Based on this update, the Company have concluded that the potential risks may outweigh the benefits for the studied patient populations. This determination reflects the totality of emerging safety information, including previously reported safety risks. Prioritizing patient safety above all else, the Company has therefore decided to terminate all rocatinlimab clinical trials currently underway.

2. Future Development Plan

This matter does not constitute an immediate determination to discontinue the entire rocatinlimab development program. However, at this point in time, the Company considers the likelihood of continuing development or resuming clinical trials to be extremely low.

3. Future Outlook

The impact of this matter on the Company's business performance is currently under review. For the fiscal year ending December 31, 2026, expenses related to commercialization preparation (SG&A expenses) and clinical trial activities (R&D expenses) for rocatinlimab, which had been incorporated into the consolidated earnings forecast, will no longer be incurred. On the other hand, additional costs associated with clinical trial closing procedures and other related expenses are expected to arise.

The earnings forecast reflecting these impacts is scheduled to be disclosed in the announcement of

the financial results for the first quarter of fiscal year 2026 on May 7, 2026.

End